MyFinsight
Home
Blog
About
Contact
Download
Download image
Proceeds from exercise of
warrants, net of expense of...
$2,088K
Proceeds from exercise of
options
$493K
Maturities of short-term
investments
$71,111K
Sales of short-term
investments
$2,135K
Net cash provided by
financing activities
$2,581K
Net cash provided by
investing activities
$1,342K
Canceled cashflow
$71,904K
Net change in cash
and cash...
-$34,000K
Canceled cashflow
$3,923K
Stock-based compensation
expense
$5,693K
Accounts payable and
accrued liabilities
$2,202K
Accounts receivable and
unbilled receivable
-$591K
Prepaid expenses and
other current assets
-$557K
Amortization of right-of-use
assets
$540K
Depreciation
$364K
Purchases of short-term
investments
$71,860K
Capital expenditures
$44K
Net cash used in
operating activities
-$37,923K
Canceled cashflow
$9,947K
Net loss
-$45,851K
Accretion of discounts on
short-term investments,...
$848K
Operating lease
liabilities
-$691K
Other assets
$480K
Back
Back
Cash Flow
source: myfinsight.com
Cardiff Oncology, Inc. (CRDF)
Cardiff Oncology, Inc. (CRDF)